Using Metformin to Help Patients with Urothelial Cancer Live Longer
Author Information
Author(s): Lee Hsiang Ying, Lin Po‐Hung, Pang See‐Tong, Fang Jen‐Kai, Tsai Chung‐You, Tsai Yao‐Chou, Chen Yung‐Tai, Chen Wei‐Chieh, Yeh Hsin‐Chih, Li Wei‐Ming
Primary Institution: Kaohsiung Medical University Hospital
Hypothesis
Can metformin improve survival outcomes in patients with upper tract urothelial carcinoma (UTUC) and type 2 diabetes?
Conclusion
Metformin use in UTUC patients with diabetes is associated with improved overall and cancer-specific survival, but not bladder recurrence-free survival.
Supporting Evidence
- Patients treated with metformin had a lower risk of cancer-specific death.
- Metformin use was associated with improved overall survival.
- No significant association was found between metformin use and bladder recurrence-free survival.
Takeaway
This study found that patients with a type of kidney cancer who took metformin lived longer than those who didn't take it.
Methodology
This retrospective study analyzed data from 940 patients with UTUC and type 2 diabetes, comparing those treated with metformin to those who were not.
Potential Biases
Potential biases due to the retrospective nature of the study and the lack of control over treatment timing.
Limitations
The study is retrospective, and the timing of metformin exposure relative to UTUC diagnosis is unknown.
Participant Demographics
Patients included were from Taiwan, with a higher incidence of UTUC compared to Western countries.
Statistical Information
P-Value
0.018 for cancer-specific survival, 0.024 for overall survival
Confidence Interval
95% CI (0.417–0.920) for CSS, 95% CI (0.532–0.956) for OS
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website